ArticleFrontiers in public health2025
Global burden and future projections of geriatric gout (1990-2021): a comprehensive analysis and Bayesian Age-Period-Cohort modeling.
Article in Frontiers in public health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Efficacy and Safety of Firsekibart in Patients with Acute Gout Unsuitable for Standard Therapy: 48-Week Results from an Open-Label Extension of a Randomized Phase 3 Trial.Advances in therapy · 2026Trial
- Trends in lung cancer burden, risk factors, and disease projections in China and the United States, 1990-2023.Chinese medical journal pulmonary and critical care medicine · 2026Article
- Exploring the global, regional, and Chinese disease burden of acute glomerulonephritis from 1990 to 2021 and future trends up to 2039 based on the 2021 Global Burden of Disease Database.International urology and nephrology · 2026Article
- Global trends in age at onset of gout, 1990-2023: a sex-stratified and forecast analysis of the Global Burden of Disease Study 2023.Clinical rheumatology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Gout is increasingly recognized as a major chronic condition among older adults, contributing significantly to global disease burden, healthcare costs, and disability. Methods: This study utilized data from the Global Burden of Disease (GBD) database, covering 204 countries and regions from 1990 to 2021. We evaluated age-standardized incidence rates, prevalence, and Years Lived with Disability (YLDs) of gout among individuals aged 60 years and older. Inequality and frontier analyses were conducted to explore disparities, and Bayesian Age-Period-Cohort (BAPC) models were applied for future trend projections up to 2036. Results: All indicators-incidence, prevalence, and YLDs-showed a steady increase across the study period, with particularly rapid growth observed in high Socio-demographic Index (SDI) regions and among older women. Although the burden was concentrated in high SDI countries, increasing trends were also evident in low SDI areas. Significant heterogeneity was found among countries with similar SDI levels. Discussion: The projected rise in gout burden through 2036 underscores the urgent need for targeted public health strategies. Disparities across SDI groups suggest that medical infrastructure, prevention programs, and cultural contexts play critical roles in disease control. Comprehensive interventions are essential to manage this growing challenge, especially among high-risk older populations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.